• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Convalescent plasma as a potential therapy for COVID-19.康复期血浆作为治疗新冠肺炎的一种潜在疗法。
Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.
2
Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives.用于应对新冠病毒的免疫球蛋白或康复期血浆：争取时间拯救生命——现状与展望
Swiss Med Wkly. 2020 Apr 28;150:w20264. doi: 10.4414/smw.2020.20264. eCollection 2020 Apr 20.
3
Why should we use convalescent plasma for COVID-19?我们为什么要将康复期血浆用于治疗新冠肺炎？
Eur J Intern Med. 2020 Jul;77:150-151. doi: 10.1016/j.ejim.2020.05.019. Epub 2020 May 16.
4
Convalescent plasma for patients with COVID-19.新冠康复者血浆用于新冠肺炎患者。
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12528. doi: 10.1073/pnas.2006961117. Epub 2020 May 12.
5
Convalescent plasma for covid-19.用于治疗新冠病毒肺炎的康复期血浆
BMJ. 2020 Sep 15;370:m3516. doi: 10.1136/bmj.m3516.
6
Challenges of Convalescent Plasma Therapy on COVID-19.恢复期血浆疗法治疗新冠病毒肺炎面临的挑战
J Clin Virol. 2020 Jun;127:104358. doi: 10.1016/j.jcv.2020.104358. Epub 2020 Apr 10.
7
[Use of convalescent plasma for COVID-19 treatment. History and evidence].[康复期血浆用于新型冠状病毒肺炎治疗。历史与证据]
Medicina (B Aires). 2020;80 Suppl 3:82-86.
8
Convalescent Plasma and COVID-19.康复期血浆与2019冠状病毒病
JAMA. 2020 Aug 4;324(5):524. doi: 10.1001/jama.2020.10699.
9
The resurgence of convalescent plasma therapy.恢复期血浆疗法的复兴。
Lancet Haematol. 2020 May;7(5):e353. doi: 10.1016/S2352-3026(20)30117-4.
10
Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?从康复期血浆制备的同种疗法药物能否作为治疗 COVID-19 的一种选择？
Homeopathy. 2020 Aug;109(3):184-185. doi: 10.1055/s-0040-1714061. Epub 2020 Jul 9.

引用本文的文献

1
SARS-CoV-2 RNA-binding protein suppresses extracellular miRNA release.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）RNA结合蛋白抑制细胞外微小RNA（miRNA）释放。
RNA Biol. 2025 Dec;22(1):1-17. doi: 10.1080/15476286.2025.2527494. Epub 2025 Jul 7.
2
Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update.对抗新型冠状病毒肺炎的新兴治疗与预防策略：简要更新
J Dig Endosc. 2020 Mar;11(1):69-72. doi: 10.1055/s-0040-1712547. Epub 2020 May 16.
3
Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial.多替拉韦对中度新冠肺炎患者的疗效：一项单中心、随机、双盲、安慰剂对照试验。
Bioimpacts. 2024 Jun 26;15:29952. doi: 10.34172/bi.29952. eCollection 2025.
4
Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.探索新冠病毒治疗领域：揭示关于美国食品药品监督管理局批准药物、疫苗接种目标及新兴策略的新观点
Molecules. 2024 Nov 25;29(23):5564. doi: 10.3390/molecules29235564.
5
Retrospective Analysis of Coronavirus SARS-CoV-2 Antibody Levels in COVID-19 Convalescent Plasma From Blood Donors.新冠康复献血者血浆中新型冠状病毒SARS-CoV-2抗体水平的回顾性分析
Can J Infect Dis Med Microbiol. 2024 Dec 5;2024:4366502. doi: 10.1155/cjid/4366502. eCollection 2024.
6
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.冠状病毒感染的叙述性概述：临床体征和症状、病毒进入和复制、治疗方式和管理。
Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058.
7
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.从检测到防护：抗体及其在诊断和对抗新冠病毒中的关键作用。
Vaccines (Basel). 2024 Apr 25;12(5):459. doi: 10.3390/vaccines12050459.
8
The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019.2019冠状病毒病恢复期血浆治疗的进展与挑战
Infect Dis Immun. 2021 Apr 20;1(1):52-58. doi: 10.1097/01.ID9.0000733568.58627.47. eCollection 2021 Apr.
9
Modelling the impact of plasma therapy and immunotherapy for recovery of COVID-19 infected individuals.模拟血浆疗法和免疫疗法对新冠病毒感染患者康复的影响。
Sao Paulo J Math Sci. 2021;15(1):344-364. doi: 10.1007/s40863-021-00232-5. Epub 2021 Apr 12.
10
Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen-Antibody Interactions in Convalescent Plasma Therapy.用于评估SARS-CoV-2发病机制的智能微流控平台原型，同时评估潜在候选药物的有效性以及恢复期血浆疗法中的抗原-抗体相互作用。
Trans Indian Natl Acad Eng. 2020;5(2):241-250. doi: 10.1007/s41403-020-00148-0. Epub 2020 Jul 8.

本文引用的文献

1
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.临床证据不支持使用皮质类固醇治疗2019新型冠状病毒肺炎肺损伤。
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
2
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
3
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.体内通过抗HIV-1的广泛中和抗体增强对HIV-1感染细胞的清除。
Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.
4
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.使用单克隆抗体3BNC117进行的HIV-1治疗引发宿主针对HIV-1的免疫反应。
Science. 2016 May 20;352(6288):997-1001. doi: 10.1126/science.aaf0972. Epub 2016 May 5.
5
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.中东呼吸综合征冠状病毒感染患者恢复期血浆治疗的可行性、安全性、临床及实验室效应：一项研究方案。
Springerplus. 2015 Nov 19;4:709. doi: 10.1186/s40064-015-1490-9. eCollection 2015.
6
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.恢复期血浆和高效免疫球蛋白治疗病毒性病因严重急性呼吸道感染的有效性：系统评价与探索性Meta分析
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.
7
Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.静注人免疫球蛋白（pH4）治疗严重 2009 年甲型 H1N1 流感的多中心、双盲、随机对照临床研究
Chest. 2013 Aug;144(2):464-473. doi: 10.1378/chest.12-2907.
8
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.恢复期血浆治疗可降低严重大流行流感 A（H1N1）2009 病毒感染患者的死亡率。
Clin Infect Dis. 2011 Feb 15;52(4):447-56. doi: 10.1093/cid/ciq106. Epub 2011 Jan 19.
9
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?荟萃分析：用于西班牙流感肺炎的恢复期血液制品：未来治疗H5N1的方法？
Ann Intern Med. 2006 Oct 17;145(8):599-609. doi: 10.7326/0003-4819-145-8-200610170-00139. Epub 2006 Aug 29.
10
Treatment of severe acute respiratory syndrome.严重急性呼吸综合征的治疗
Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91. doi: 10.1007/s10096-005-0004-z.

Convalescent plasma as a potential therapy for COVID-19.

作者信息

Chen Long, Xiong Jing, Bao Lei, Shi Yuan

机构信息

Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; China International Science and Technology Cooperation base of Child development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.

Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; China International Science and Technology Cooperation base of Child development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.

出版信息

Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.

DOI:10.1016/S1473-3099(20)30141-9
PMID:32113510
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7128218/
Abstract
摘要